People
-
MannKind Corporation has announced the appointment of Michael Castagna as Chief Executive Officer, effective May 25, 2017. Castagna takes over the role from Matthew Pfeffer, who succeeded Alfred Mann as CEO in January 2016. Pfeffer… Read more . . .
-
Elran Haber, CEO of Therapix Biosciences, which is developing intranasal cannabinoid-based drugs, will step down “to pursue other professional opportunities” after the company concludes its search for “a permanent, US based Chief Executive Officer,” the… Read more . . .
-
Arikayce inhaled amikacin deveoper Insmed Incorporated has announced the appointments of Paolo Tombesi as Chief Financial Officer, Paul Streck as Chief Medical Officer, and Eugene Sullivan as Chief Product Strategy Officer. Tombesi was most recently… Read more . . .
-
Inhaled drug developer Pulmatrix has announced the appointment of former Sunovion Respiratory and CNS Business Unit Head Ted Raad as Chief Business Officer. Raad was most recently Chief Commercial Officer at Option Care, the home… Read more . . .
-
Digital health company Cohero Health has announced the appointment of Joe Condurso as CEO. Cohero and its partner Presspart introduced their eMDI smart inhaler system at DDL in 2016. Condurso was most recently CEO of… Read more . . .
-
Verona Pharma has announced a clinical development services agreement with QuintilesIMS for Verona’s RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. The company also said that it is planning… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that Lars Asking, who has served as VP of MVIC since May 2016, will become CEO of the consortium as of May 2017. Asking will take over… Read more . . .
-
Milestone Pharmaceuticals has announced the appointment of Joseph G. Oliveto as President and CEO. Oliveto, who was most recently CEO of Galleon Pharmaceuticals and previously served as President and CEO of Chelsea Therapeutics, is replacing… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has announced the appointment of former MAP Pharmaceuticals President and CEO Timothy S. Nelson as Independent Director of the Board of Directors. Nelson led MAP Pharmaceuticals when it was acquired… Read more . . .
-
Lovelace Biomedical, a not-for-profit research organization which offers inhalation toxicology and other services for inhaled drug development, has announced the appointment of Larry Mallis as Director of Bioanalytical Operations. Mallis was most recently Director of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA